[1]戴伊奇,王书楠,国巍,等.硼替佐米治疗人免疫缺陷病毒阴性浆母细胞淋巴瘤3例报告并文献复习[J].第三军医大学学报,2018,40(04):334-339.
 DAI Yiqi,WANG Shunan,GUO Wei,et al.Bortezomib in treatment of HIV-negative plasmablastic lymphoma: report of 3 cases and literature review[J].J Third Mil Med Univ,2018,40(04):334-339.
点击复制

硼替佐米治疗人免疫缺陷病毒阴性浆母细胞淋巴瘤3例报告并文献复习(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
40卷
期数:
2018年第04期
页码:
334-339
栏目:
临床医学
出版日期:
2018-02-28

文章信息/Info

Title:
Bortezomib in treatment of HIV-negative plasmablastic lymphoma: report of 3 cases and literature review
作者:
戴伊奇王书楠国巍白鸥
吉林大学第一医院肿瘤中心血液科
Author(s):
DAI Yiqi WANG Shunan GUO Wei BAI Ou

Department of Hematology, Cancer Center, First Hospital of Jilin University, Changchun, Jilin Province, 130021, China

关键词:
浆母细胞淋巴瘤硼替佐米人免疫缺陷病毒
Keywords:
plasmablastic lymphoma bortezomib human immunodeficiency virus
分类号:
R733.4;R979.1
文献标志码:
A
摘要:

目的    提高对人免疫缺陷病毒(human immunodeficiency virus,HIV)阴性浆母细胞淋巴瘤(plasmablastic lymphoma,PBL)的临床特征、治疗及预后的认识。方法    回顾性分析吉林大学第一医院肿瘤中心血液科2015-2016年收治的应用硼替佐米治疗的3例HIV阴性PBL患者的临床资料,分析其临床特征及转归。结果    ① 3例HIV阴性PBL患者均为男性,年龄分别为42、43、35岁;其中2例以腹部症状起病,1例以淋巴结肿大起病;均无导致免疫功能低下的疾病或状态。② 2例有结外受累,1例有骨髓受累;根据淋巴瘤Ann Arbor分期分别为ⅠA、ⅢA、ⅣB期。③病理:均表现弥漫大B细胞淋巴瘤的形态学特点;具有典型的浆细胞表型;Ki-67指数分别为80%、70%、40%。④治疗:3例均采用了以硼替佐米为基础的联合化疗方案,1例完全缓解(clinical complete response,CR),2例部分缓解(partly remission,PR),无进展生存期(progressionfree survival,PFS)分别为1、6、10个月,总生存期(overall survival,OS)分别为5个月、7个月、未获得。结论    该组人免疫缺陷病毒阴性浆母细胞淋巴瘤患者以中青年为主,疾病呈高侵袭性;临床分期为晚期及Ki67高的患者预后差;硼替佐米用于治疗浆母细胞淋巴瘤需要临床进一步观察。

Abstract:

Objective    To better understand the clinical features, treatment and prognosis of HIV-    negative plasmablastic lymphoma (PBL). Methods    The clinical data were reviewed for 3 cases of HIVnegative PBL treated with bortezomib in our department between January, 2015 and December, 2016. The clinical features and outcomes of the patients were analyzed retrospectively. Results    All these 3 patients were male and aged 42, 43, and 35 years. Two of the patients presented with gastrointestinal discomfort and the other patient had lymphadenopathy as the initial symptom. None of them had underlying immunosuppressive state. Extranodular involvement was found in 2 patients and bone marrow involvement in the other, and they were in stage Ⅳ, stage Ⅲ, and stage Ⅰ according to Ann Arbor Staging. Pathological examination revealed morphological features of diffuse large B cell lymphoma and typical immunophenotypic characteristics of plasma cells in all the 3 patients, and their Ki-67 index was 80%, 70%, and 40%. All the patients received bortezomib-based chemotherapy, and complete response was achieved in 1 patient and partial responses in the other 2. The progression-free survival of the 3 patients was 1, 6 and 10 months with overall survival of 5, 7 and over 22 months, respectively. Conclusion    The patients with HIV-negative PBL are mainly at the middle age upon disease onset. HIV-negative PBL is highly aggressive, and the patients in advanced stage or with a high Ki-67 index at the diagnosis often have a poor prognosis. The efficacy of bortezomib for treatment of PBL still needs further investigation.

参考文献/References:

[1]STEIN H, HARRIS N, CAMPO E, et al. WHO classification of tumors of the hematopoietic and lymphoid tissues[M]. 4th Eds IARC: Lyon, 2008: 256-257. DOI: 10.1007/9781 493971428_3.
[2]CARBONE A, GLOGHINI A. Plasmablastic lymphoma: one or more entities[J]. Am J Hematol, 2008, 83(10): 763-764. DOI: 10.1002/ajh.21259. 
[3]MORSCIO J, DIERICKX D, NIJS J, et al. Clinicopathologic comparison of plasmablastic lymphoma in HIVpositive, immunocompetent, and posttransplant patients: singlecenter series of 25 cases and metaanalysis of 277 reported cases[J]. Am J Surg Pathol, 2014, 38(7): 875-886. DOI: 10.1097/PAS.0000000000000234. 
[4]CASTILLO J J, BIBAS M, MIRANDA R N. The biology and treatment of plasmablastic lymphoma[J]. Blood, 2015, 125(15): 2323-2330. DOI: 10.1182/blood201410567479. 
[5]VAN VRANCKEN M J, KEGLOVITS L, KRAUSE J. Plasmablastic lymphoma following transplantation [J]. Proc (Bayl Univ Med Cent), 2013, 26(2): 152-155. 
[6] WU J Z, MIN K, FAN L, et al. Plasmablastic lymphoma following combination treatment with fludarabine and rituximab for nongastric mucosaassociated lymphoid tissue lymphoma: a case report and review of literature [J]. Int J Clin Exp Pathol,2014,7(7): 4400-4407. 
[7]陈玉,刘艳辉,罗东兰,等.人免疫缺陷病毒阴性的浆母细胞性淋巴瘤临床病理观察[J]. 中华病理学杂志, 2015, 44(8): 548-552. DOI: 10.3760/cma.j.issn.05295807. 2015.08.002.
CHEN Y, LIU Y H, LUO D L, et al. Clinicopathologic analysis of HIVnegative plasmablastic lymphoma [J]. Chin J Pathol, 2015, 44(8): 548-552. DOI: 10.3760/cma.j.issn.05295807.2015.08.002.
[8]李芬, 丁文双, 左着, 等. 浆母细胞性淋巴瘤11例临床病理分析及文献复习[J]. 中华病理学杂志, 2016, 45(1): 37-42. DOI: 10.3760/cma.j.issn.05295807.2016.01.009.
LI F, DING W S, ZUO Z, et al. Plasmablastic lymphoma: a clinicopathologic analysis of 11 cases with review of literature[J]. Chin J Pathol, 2016, 45(1): 37-42. DOI: 10.3760/cma.j.issn.05295807.2016.01.009.
[9]桂琳, 何小慧, 刘鹏, 等. 9例人免疫缺陷病毒阴性的浆母细胞淋巴瘤临床特征及文献复习[J]. 中华血液学杂志, 2016, 37(9): 762-767. DOI: 10.3760/cma.j.issn.02532727.2016. 09.007.
GUI L, HE X H, LIU P, et al. Clinical features and outcomes: analysis of 9 cases of HIVnegtive plasmablastic lymphoma[J]. Chin J Hematol, 2016, 37(9): 762-767. DOI: 10.3760/cma.j.issn.02532727.2016.09.007.
[10]LAURENT C, FABIANI B, DO C, et al.Immunecheckpoint expression in EpsteinBarr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients[J]. Haematologica, 2016, 101(8): 976-984. DOI: 10.3324/haematol.2016.141978.
[11]LIU M, LIU B, LIU B, et al. Human immunodeficiency virusnegative plasmablastic lymphoma: a comprehensive analysis of 114 cases [J]. Oncol Rep, 2015, 33(4): 1615-1620. DOI: 10.3892/or.2015.3808.
[12]TCHERNONOG E, FAURIE P, COPPO P, et al. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group [J]. Ann Oncol, 2017, 28(4): 843-848. DOI: 10.1093/annonc/mdw684.
[13]CASTILLO J J, WINER E S, STACHURSKI D, et al. Clinical and pathological differences between human immunodeficiency viruspositive and human immunodeficiency virusnegative patients with plasmablastic lymphoma[J]. Leuk Lymphoma, 2010, 51(11): 2047-2053. DOI: 10.3109/10428194.2010.516040. 
[14]CASTILLO J J, REAGAN J L. Plasmablastic lymphoma: a systematic review[J]. Sci World J, 2011, 11: 687-696. DOI: 10.1100/tsw.2011.59. 
[15]CASTILLO J, PANTANOWITZ L, DEZUBE B J. HIVassociated plasmablastic lymphoma: lessons learned from 112 published cases [J]. Am J Hematol, 2008, 83(10): 804-809. DOI: 10.1002/ajh.21250. 
[16]CASTILLO J J, WINER E S, STACHURSKI D, et al. Prognostic factors in chemotherapytreated patients with HIVassociated plasmablastic lymphoma [J]. Oncologist, 2010, 15(3): 293-299. DOI: 10.1634/theoncologist.20090304. 
[17]ALMALKI M M, CASTILLO J J, SLOAN J M, et al. Hematopoietic cell transplantation for plasmablastic lymphoma: a review[J]. Biol Blood Marrow Transplant, 2014, 20(12): 1877-1884. DOI: 10.1016/j.bbmt.2014.06. 009. 
[18]DUNLEAVY K, WILSON W H. How I treat HIVassociated lymphoma[J]. Blood, 2012, 119(14): 3245-3255. DOI: 10.1182/blood201108373738. 
[19]CATTANEO C, FINEL H, MCQUAKER G, et al. Autologous hematopoietic stem cell transplantation for plasmablastic lymphoma: the european society for blood and marrow transplantation experience [J]. Biol Blood Marrow Transplant, 2015, 21(6): 1146-1147. DOI: 10.1016/j. bbmt.2015.03.008. 
[20]LIU J J, ZHANG L, AYALA E, et al. Human immunodeficiency virus (HIV)negative plasmablastic lymphoma: a single institutional experience and literature review[J]. Leuk Res, 2011, 35(12): 1571-1577. DOI: 10. 1016/j.leukres.2011.06.023. 
[21]CASTILLO J J, REAGAN J L, SIKOV W M, et al. Bortezomib in combination with infusional doseadjusted EPOCH for the treatment of plasmablastic lymphoma[J]. Br J Haematol, 2015, 169(3): 352-355. DOI: 10.1111/bjh.13300. 
[22]CENCINI E, FABBRI A, GUERRINI S, et al. Longterm remission in a case of plasmablastic lymphoma treated with COMP (cyclophosphamide, liposomal doxorubicin, vincristine, prednisone) and bortezomib[J]. Eur J Haematol, 2016, 96(6): 650-654. DOI: 10.1111/ejh.12732. 
[23]FERNANDEZALVAREZ R, GONZALEZRODRIGUEZ A P, RUBIOCASTRO A, et al. Bortezomib plus CHOP for the treatment of HIVassociated plasmablastic lymphoma: clinical experience in three patients [J]. Leuk Lymphoma, 2015, 18: 1-4. DOI: 10.3109/10428194.2015.1050666.
[24]FEDELE P L, GREGORY G P, GILBERTSON M, et al. Infusional doseadjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma[J]. Ann Hematol, 2016, 95(4): 667-668. DOI: 10.1007/s00277-016-2601-6. 
[25]SABA N S, DANG D, SABA J, et al. Bortezomib in plasmablastic lymphoma: a case report and review of the literature[J]. Onkologie, 2013, 36(5): 287-291. DOI: 10. 1159/000350325. 
[26]BIBAS M, GRISETTI S, ALBA L, et al. Patient with HIVassociated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone[J]. J Clin Oncol, 2010, 28(34): e704-e708. DOI: 10.1200/JCO.2010.30.0038. 
[27]CARRAS S, REGNY C, PEOC’H M, et al. Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric nonhuman immunodeficiency virusassociated plasmablastic lymphoma[J]. Leuk Lymphoma, 2015, 56(10): 2986-2988. DOI: 10.3109/10428194.2015.1016931. 
[28]YANAMANDRA U, SAHU K K, JAIN N, et al. Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings[J]. Ann Hematol, 2016, 95(10): 1715-1717. DOI: 10.1007/s0027701627329. 
[29]HOLDERNESS B M, MALHOTRA S, LEVY N B, et al. Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia[J]. J Clin Oncol, 2013, 31(12): e197-e199. DOI: 10.1200/JCO.2012.46.9593. 
[30]YAN M, DONG Z, ZHAO F, et al. CD20positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab[J]. Eur J Haematol, 2014, 93(1): 77-80. DOI: 10.1111/ejh.12286.

相似文献/References:

[1]谢燕,喻秀丽,童立纺.硼替佐米对A549细胞增殖及p21、p27表达的影响[J].第三军医大学学报,2012,34(17):1775.
 Xie Yan,Yu Xiuli,Tong Lifang.Anti-proliferation effect of proteasome inhibitor bortezomib in human lung adenocarcinoma A549 cells[J].J Third Mil Med Univ,2012,34(04):1775.
[2]李佳丽,刘耀,曾东风,等.硼替佐米联合地塞米松和沙利度胺治疗多发性骨髓瘤的临床研究[J].第三军医大学学报,2012,34(24):2515.
 Li Jiali,Liu Yao,Zeng Dongfeng,et al.Bortezomib combined with dexamethasone and thalidomide in treatment of multiple myeloma: report of 58 cases[J].J Third Mil Med Univ,2012,34(04):2515.
[3]杨再林,张勇,张伶,等.硼替佐米联合化疗对多发性骨髓瘤的疗效与相关血液学指标分析[J].第三军医大学学报,2010,32(09):975.
 Yang Zailin,Zhang Yong,Zhang Ling,et al.Effect of bortezomib in combination with chemotherapy on multiple myeloma and change in its hematological indexes[J].J Third Mil Med Univ,2010,32(04):975.
[4]樊锐太,胡勇,刘俊启,等.硼替佐米对U87胶质瘤放射增敏及细胞周期分布的影响[J].第三军医大学学报,2012,34(08):758.
 Fan Ruitai,Hu Yong,Liu Junqi,et al.Effect of bortezomib on radiosensitivity of U87 glioma and distribution of cell cycle[J].J Third Mil Med Univ,2012,34(04):758.

更新日期/Last Update: 2018-03-03